UroGen Pharma reported $68 million in revenue for its cancer drug ZUSDURI in Q3 2026, marking 35% growth from the previous quarter. The FDA accepted the New Drug Application for UGN-103, a next-gen mitomycin formulation, with a target decision date set for June 14, 2027. The company also initiated a Phase 1 trial for UGN-501, an investigational oncolytic virus for bladder cancer. These developments highlight UroGen's expanding portfolio and growth potential in urothelial cancer treatments.
UroGen Pharma's reported $68 million revenue for its cancer drug ZUSDURI in Q3 2026 provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 23 fell. Notable movers include OSCR at USD 35.20 with a 1-day change of +8.61% and Pluang order activity of 16% Sell / 84% Buy, BRKR at USD 60.45 up 6.99%, and AMGN at USD 489.98 up 6.23% with 32% Sell / 68% Buy activity and a typical hold time of 73 days.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
